Table 5.
. Associations of post-finasteride-treatment 5α-androstane-3α,17β-diol glucuronide, sex steroid hormones and sex hormone binding globulin with prostate cancer risk.
| Overall Cancer | Gleason 2–6 | Gleason 7–10 | Gleason 8–10 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Range of values | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | |
| 3α-dG1 | <(1.0) | 135/164 | ref | 82/164 | ref | 49/164 | ref | 15/164 | ref |
| (ng/mL) | (1.0) to <(1.4) | 127/171 | 0.89 (0.63–1.24) | 78/171 | 0.88 (0.60–1.30) | 45/171 | 0.88 (0.55–1.40) | 11/171 | 0.70 (0.31–1.58) |
| (1.4) to <(2.1) | 137/170 | 0.99 (0.71–1.38) | 78/170 | 0.90 (0.61–1.33) | 54/170 | 1.11 (0.71–1.75) | 17/170 | 1.14 (0.54–2.40) | |
| ≥ (2.1) | 130/169 | 0.96 (0.68–1.34) | 64/169 | 0.74 (0.49–1.11) | 60/169 | 1.28 (0.82–2.00) | 25/169 | 1.81 (0.91–3.60) | |
| 0.96 | 0.18 | 0.17 | 0.04 | ||||||
| Testosterone | <(318) | 137/168 | ref | 76/168 | ref | 55/168 | ref | 19/168 | ref |
| (ng/dL) | (318) to <(398) | 132/169 | 0.94 (0.67–1.32) | 71/169 | 0.87 (0.58–1.30) | 58/169 | 1.10 (0.71–1.72) | 16/169 | 0.94 (0.46–1.94) |
| (398) to <(494) | 120/168 | 0.83 (0.58–1.19) | 71/168 | 0.82 (0.54–1.25) | 45/168 | 0.86 (0.53–1.40) | 15/168 | 0.92 (0.43–1.98) | |
| >≥ (494) | 139/169 | 1.11 (0.75–1.64) | 83/169 | 1.06 (0.66–1.68) | 50/169 | 1.14 (0.67–1.94) | 18/169 | 1.38 (0.60–3.15) | |
| 0.84 | 0.92 | 0.92 | 0.52 | ||||||
| Free Testosterone | <(7.3) | 138/168 | ref | 72/168 | ref | 62/168 | ref | 24/168 | ref |
| (ng/dL) | (7.3) to <(9.1) | 138/170 | 0.95 (0.68–1.33) | 77/170 | 0.97 (0.65–1.44) | 54/170 | 0.89 (0.58–1.38) | 12/170 | 0.55 (0.26–1.16) |
| (9.1) to <(11.) | 146/169 | 1.09 (0.78–1.51) | 94/169 | 1.26 (0.85–1.86) | 50/169 | 0.90 (0.58–1.40) | 16/169 | 0.83 (0.41–1.65) | |
| ≥ (11.2) | 106/167 | 0.83 (0.59–1.19) | 58/167 | 0.81 (0.53–1.24) | 42/167 | 0.81 (0.51–1.30) | 16/167 | 0.91 (0.45–1.83) | |
| 0.51 | 0.69 | 0.40 | 0.92 | ||||||
| Estrone | <(39.4) | 109/167 | ref | 56/167 | ref | 47/167 | ref | 11/167 | ref |
| (pg/mL) | (39.4) to <(49.0) | 139/167 | 1.27 (0.90–1.78) | 79/167 | 1.37 (0.91–2.07) | 57/167 | 1.24 (0.79–1.94) | 23/167 | 2.19 (1.03–4.67) |
| (49.0) to <(59.2) | 128/171 | 1.19 (0.84–1.68) | 78/171 | 1.41 (0.93–2.13) | 47/171 | 1.01 (0.64–1.61) | 14/171 | 1.28 (0.56–2.93) | |
| ≥ (59.2) | 145/162 | 1.54 (1.09–2.17) | 84/162 | 1.74 (1.15–2.63) | 55/162 | 1.35 (0.85–2.13) | 20/162 | 2.11 (0.97–4.59) | |
| 0.03 | 0.01 | 0.35 | 0.21 | ||||||
| Total Estradiol | <(29.1) | 121/169 | ref | 72/169 | ref | 44/169 | ref | 14/169 | ref |
| (pg/mL) | (29.1) to <(35.2) | 117/168 | 1.04 (0.74–1.47) | 58/168 | 0.86 (0.57–1.31) | 53/168 | 1.31 (0.82–2.08) | 17/168 | 1.33 (0.63–2.81) |
| (35.2) to <(42.4) | 122/162 | 1.15 (0.81–1.62) | 72/162 | 1.15 (0.77–1.72) | 46/162 | 1.18 (0.73–1.90) | 16/162 | 1.26 (0.59–2.70) | |
| ≥ (42.4) | 167/171 | 1.49 (1.07–2.07) | 98/171 | 1.45 (0.98–2.13) | 65/171 | 1.62 (1.03–2.56) | 21/171 | 1.64 (0.79–3.41) | |
| 0.02 | 0.03 | 0.06 | 0.22 | ||||||
| Free Estradiol | <(0.77) | 124/170 | ref | 69/170 | ref | 49/170 | ref | 14/170 | ref |
| (pg/mL) | (0.77) to <(0.92) | 106/167 | 0.89 (0.63–1.26) | 61/167 | 0.93 (0.62–1.41) | 41/167 | 0.86 (0.53–1.38) | 14/167 | 1.02 (0.47–2.23) |
| (0.92) to <(1.14) | 145/162 | 1.33 (0.95–1.86) | 80/162 | 1.35 (0.91–2.02) | 60/162 | 1.35 (0.87–2.11) | 21/162 | 1.65 (0.80–3.38) | |
| ≥ (1.14) | 152/171 | 1.34 (0.96–1.87) | 90/171 | 1.44 (0.97–2.14) | 58/171 | 1.28 (0.81–2.00) | 19/171 | 1.47 (0.70–3.07) | |
| 0.02 | 0.02 | 0.11 | 0.18 | ||||||
1
5α-androstane-3α,17β-diol glucuronide
2
Adjusted for age, race, family history of prostate cancer, SHBG, body mass index and serum cholesterol.